Target intelligence / Profile preview

Luminal carbohydrate substrates leading to short-chain fatty acid production

Molecular classification
Carbohydrate, Prebiotic, Metabolic substrate
01

Overview

Luminal carbohydrate substrates refer to a diverse group of non-digestible dietary fibers and prebiotics, such as inulin, resistant starch, and fructo-oligosaccharides, that escape enzymatic digestion in the small intestine and reach the colon (Gibson et al., 2017). In the large intestine, these substrates are fermented by the commensal microbiota, a process that generates short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate (Koh et al., 2016). These SCFAs serve as the primary energy source for colonocytes and function as critical signaling molecules that regulate gut barrier integrity, immune homeostasis, and systemic metabolism (Blaak et al., 2020). While not a single molecular target like a receptor, these substrates are therapeutic focal points for modulating the gut-brain and gut-immune axes to treat conditions such as inflammatory bowel disease and metabolic syndrome (Sun et al., 2017). Their physiological effects are largely mediated through the activation of G protein-coupled receptors, specifically FFAR2 and FFAR3, and the inhibition of histone deacetylases (Tan et al., 2014). Consequently, the availability and fermentation of these carbohydrates are essential for maintaining a healthy symbiotic relationship between the host and the gut microbiome.

Other names
Dietary fiberPrebioticsFermentable carbohydratesNon-digestible carbohydratesMicrobiota-accessible carbohydrates (MACs)
02

Mechanism of action

Microbial fermentation of non-digestible carbohydrates in the colon produces short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which then activate G protein-coupled receptors (FFAR2, FFAR3) and inhibit histone deacetylases (Koh et al., 2016; Tan et al., 2014).

03

Biological functions

Microbial fermentationEnergy productionIntestinal barrier regulationImmune modulationMetabolic signaling
04

Disease associations

Inflammatory bowel diseaseObesityType 2 diabetesColorectal cancerMetabolic syndrome
05

Safety considerations

Gastrointestinal distressFlatulenceAbdominal bloatingOsmotic diarrhea
06

Interacting drugs

Inulin

5 more in the full profile.

07

Biomarkers

Fecal short-chain fatty acid concentrationGut microbiota compositionBreath hydrogen levelsFecal pH

Beyond the preview

Go deeper on Luminal carbohydrate substrates leading to short-chain fatty acid production.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luminal carbohydrate substrates leading to short-chain fatty acid production.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call